HRD-positive tumors may show sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors, while MMR-deficient leiomyosarcoma may respond to immune checkpoint blockade therapies (Table 2) [46]. Here, MRC1 is linked to leiomyosarcoma.